New hope for toughest lymphomas: experimental combo targets Cancer's repair system
NCT ID NCT03259503
Summary
This early-stage study tested a new combination of drugs for patients with aggressive lymphomas that have come back or not responded to standard treatments. The main goal was to find the safest dose of a drug called olaparib when given with a powerful chemotherapy regimen before a stem cell transplant. Researchers hoped this combination would work better than chemotherapy alone for these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.